Brought to you by 
Second financing in a month brings in another $11.28mm for Xoma
16 Jun 2009
Executive Summary
Just weeks after netting $9.4mm, Xoma has closed on another private sale of shares. This time it netted $11.28mm through the registered direct offering of 10.4mm units to certain institutional investors at $1.15 each (a 40% premium). The units consist of one common share and a five-and-a-half-year warrant to buy half of a share (up to 5.2mm shares at $1.30 apiece). The proceeds will be used to continue developing XOMA052, an anti-IL-1 beta antibody. Canaccord Adams and Wedbush PacGrow Life Sciences were the placement agents.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Synthesis Technologies, Production Processes
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Financing
- Private Investment in Public Equity
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com